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Antigen presentation, autoantigens, 
and immune regulation in multiple 
sclerosis and other autoimmune 
diseases
Christine Riedhammer and Robert Weissert*
Neuroimmunology, Department of Neurology, University of Regensburg, Regensburg, Germany
Antigen presentation is in the center of the immune system, both in host defense against 
pathogens, but also when the system is unbalanced and autoimmune diseases like multiple 
sclerosis (MS) develop. It is not just by chance that a major histocompatibility complex 
gene is the major genetic susceptibility locus in MS; a feature that MS shares with other 
autoimmune diseases. The exact etiology of the disease, however, has not been fully 
understood yet. T cells are regarded as the major players in the disease, but most probably 
a complex interplay of altered central and peripheral tolerance mechanisms, T-cell and 
B-cell functions, characteristics of putative autoantigens, and a possible interference of 
environmental factors like microorganisms are at work. In this review, new data on all these 
different aspects of antigen presentation and their role in MS will be discussed, probable 
autoantigens will be summarized, and comparisons to other autoimmune diseases will 
be drawn.
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introduction
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS), causing a loss 
of myelin sheaths and a degeneration of axons preferably in the white matter, but also in the cortex (1).
Despite immense exploratory efforts, the pathogenesis and target antigen(s) of MS have so far 
not or only partially been identified. This problem is also present in other autoimmune disease like 
rheumatoid arthritis (RA) or type 1 diabetes mellitus (T1D). On the other hand, research has revealed 
the targets of other diseases like myasthenia gravis (MG) or neuromyelitis optica (NMO), but their 
exact pathogeneses by the interplay of different immune cells still remain unclear.
Multiple sclerosis is widely thought to be induced and perpetuated by the immune system. T cells 
are believed to have a central role in the pathogenesis of the disease. It is assumed that defects of 
central and peripheral tolerance permit an existence of self-reactive T cells, which are activated by 
antigen-presenting cells (APCs).
As different autoimmune diseases share the feature that risk is conferred by genes that are encoded 
within the major histocompatibility complex (MHC) locus, antigen presentation generally seems to be of 
great importance in autoimmune diseases. This review will point out important mechanisms of antigen 
presentation, autoantigens as well as the contribution of different types of immune cells in autoimmune 
diseases. The focus will be on MS, but other autoimmune diseases like RA, T1D, MG, NMO, and 
autoimmune encephalitides (AE) will provide comparisons concerning the genetic background, the 
ambiguity of the identified or suspected target antigens, and the underlying pathogenic mechanisms.
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Antigen Processing
Peptide fragments that are presented on MHC class I or MHC 
class II molecules are first processed within the cell before they 
reach the cell membrane on the respective MHC molecule (2). 
The processing machineries for MHC class I and MHC class II 
molecules differ. Peptides derived from the cytosol and the nucleus 
are presented on MHC class I molecules. For their processing, the 
proteasome is of paramount importance. Inhibition of proteasomal 
function can block antigen presentation (3). Interferon (IFN)-γ can 
induce the immunoproteasome, which leads to the processing of a 
different set of peptides compared to the constitutive proteasome 
(4). Apart from the proteasome, also the endoplasmic reticulum 
(ER) is important for the presentation of peptides on MHC class I 
molecules. Specialized aminopeptidases are involved in trimming 
the peptides to a length of 8–10 amino acids (5, 6). Peptides are 
subsequently loaded on MHC class I molecules. In this process, 
tapasin and the transporter associated with antigen processing 
(TAP) are involved, which are expressed in the ER (7). The binding 
groove of MHC class I molecules is closed, limiting the length of 
the presented peptides to 8–10 amino acids, even though examples 
of longer peptides presented on MHC class I molecules exist (8).
Major histocompatibility complex class II molecules bind 
antigens that are derived from extracellular proteins. These are 
taken up by endosomes and subsequently processed. The pH 
in the endosomes is very important for the control of protease 
activity (9). The binding grooves of MHC class II molecules in 
the endosomes are normally covered by the invariant chain (10). 
A specific part of the invariant chain (the CLIP) covers the groove 
and can be removed by human leukocyte antigen (HLA)-DM (11). 
Subsequently, peptides that are present in the endosomes can bind 
in the groove and be presented to T cells. The binding groove 
of MHC class II molecules is open and presented peptides are 
generally 14–18 amino acids in length. Under certain conditions, 
however, also shorter or longer peptides can be presented. While 
MHC class I molecules are present on all nucleated cells, MHC 
class II molecules are only present on specialized APCs like den-
dritic cells (DCs), B cells, and macrophages. In the CNS, microglia 
are considered as professional APCs (12). Also, astrocytes can 
present antigen on MHC class II molecules under certain condi-
tions (13). Since the uptake of antigen differs between different 
types of professional APCs, also the presented set of peptides can 
differ. In addition, also the intracellular composition of molecules 
differs regarding the antigen processing machinery (14).
There is cross-presentation of antigens in the MHC class I 
and MHC class II pathway (15, 16). Different pathways allow 
this cross-presentation. Phagosomes that take up antigen from 
the extracellular space can have ER-associated molecules. Also 
certain immunopeptidases contribute to cross-presentation (17). 
Cross-presented antigens from extracellular origin are mainly 
presented on MHC class I molecules of DCs (18).
In regard to autoimmune diseases, the exact sequence of events 
leading to the presentation of certain sets of autoantigen-derived 
peptides on APCs in humans is still incompletely deciphered. 
Potentially, all molecules involved in antigen processing and 
binding of autoantigens to MHC molecules might influence the 
emergence of autoimmune disease. Even though the role of the 
different steps in antigen processing in autoimmune diseases has 
not been fully established yet, much will be learned over the next 
years and be of potential importance for the design of new therapies.
Tolerance
The emergence of an autoimmune disease apparently requires the 
existence of self-reactive cells which escape central and peripheral 
tolerance mechanisms and become activated in some way. Self-
reactive T cells have been shown to be present both in persons with 
and without autoimmune disease (19–26). How self-tolerance is 
disrupted in autoimmune disease, however, remains to be ascer-
tained. The understanding of how tolerance mechanisms work is 
also the basis for a comprehension of potential deficiencies.
Central Tolerance
The challenge of intrathymic central tolerance induction includes 
tolerizing T cells reactive with antigens which are not expressed 
ubiquitously, but only found in particular organs (tissue-restricted 
antigens, TRAs). The intrathymic expression of TRAs can induce 
tolerance and prevent development of autoimmune disease (27). 
This is achieved by negative selection of T cells in the thymic 
medulla, where T cells exhibiting a high affinity/avidity interac-
tion between their T-cell receptor (TCR) and MHC–self-peptide 
complexes presented by medullary APCs become apoptotic. 
Medullary thymic epithelial cells (mTECs) and DCs cooperate 
to achieve this (28). The thymic transcription factor autoimmune 
regulator (AIRE) plays a fundamental role in central tolerance 
induction, as it controls the transcription of genes coding for TRAs 
(29), and is predisposed, when not working properly, to favor the 
development of autoimmune disease. Certain single nucleotide 
polymorphisms (SNPs) in the AIRE gene have been suggested 
to play a role in autoimmune diseases like RA or MG (30–32). 
Interestingly, mTECs make use of macroautophagy for presenting 
antigens also on MHC class II molecules, which enables them to 
tolerize CD4+ T cells (33). Important candidate autoantigens of MS 
and other autoimmune diseases seem to be present in the human 
thymus (34–36). Consequently, a lack of presentation of important 
self-antigens in the thymus cannot fully account for the existence 
of autoreactive T cells.
Apart from thymocytes recognizing a peptide that is only rarely 
presented in the thymus, also thymocytes expressing a TCR whose 
affinity/avidity for a peptide–MHC complex is too low to eliminate 
the thymocytes during negative selection are thought to be able to 
elude central tolerance mechanisms (37).
Post-translational modifications of self-antigens in the periph-
ery can also change the affinity/avidity of the interaction between 
a TCR and a self-peptide–MHC complex. Thus, the affinity/avidity 
between a TCR and a self-peptide–MHC complex might be low 
enough to avoid central tolerance induction, but high enough to 
lead to an activation of autoreactive T cells in the periphery after 
a post-translational modification of the antigen. For example, 
thiopalmitoylation occurs frequently with proteolipid protein 
(PLP), a putative autoantigen in MS, and it was found that post-
translationally modified PLP is more encephalitogenic than the 
unmodified form (38). Also citrullinated proteins were found more 
frequently in MS lesions than in control brain tissue (39).
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Another interesting aspect is the structural nature of the inter-
action between a TCR of a potentially self-reactive T cell and its 
respective peptide–MHC complex in the thymus. An analysis of 
the crystal structure of a TCR and a self-peptide–MHC complex 
in an MS patient showed that the TCR bound in a tilted way to 
the peptide–MHC complex (40). Such structural deviations might 
result in a low affinity/avidity of the interaction between TCR 
and self-peptide–MHC complex, so that the T cell can escape 
from central tolerance. In the periphery, however, the quantity of 
self-antigen is higher and the affinity/avidity might then be high 
enough to contribute to the pathogenesis of autoimmune disease. 
It was shown that autoreactive T-cell clones both in MS and T1D 
exhibited a lower recruitment of self-peptide–MHC complexes 
than T cells from the same patients specific for viral peptides. 
Nevertheless, the autoreactive T-cell clones proliferated vigorously 
in response to self-antigen, indicating that TCR signaling is still 
functional in these cells (41). Again, these facts might support an 
escape of negative selection and a possible activation of these cells 
in the periphery.
Peripheral Tolerance
When self-reactive T cells escape central tolerance mechanisms, 
peripheral tolerance mechanisms are required, which include 
ignorance, i.e., the physical separation of autoreactive cells and 
their target, the deletion of autoreactive cells, their inhibition, 
e.g., by a lack of costimulatory factors and their suppression by 
regulatory T cells (42).
An important factor for the inhibition of T cells is the 
function of the cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4 = CD152). Its role in MS has been investigated in many 
studies. A recent meta-analysis of genetic polymorphisms of 
the CTLA-4 gene did not reveal any associations with MS (43). 
However, there are several studies pointing toward a significance 
of costimulatory mechanisms for MS. Myelin-reactive T cells 
from MS patients were observed to be less sensitive to a lack of 
costimulation than T cells from controls (44–46). Also, another 
study found increased T cells insensitive to costimulation in MS 
patients, which predominantly produced Th1 cytokines (47). In 
active MS, increased CD80+ cells were found (48).
An important mechanism for the deletion or “activation-
induced cell death” of autoreactive cells is the interaction of Fas 
and Fas ligand, which can induce apoptosis in autoreactive T cells. 
A higher resistance of T cells to apoptosis in MS patients has been 
reported in several studies which found decreased expression of 
Fas and a lower rate of apoptosis induced by stimulation with 
mitogen in T cells from MS patients (49, 50). New data indicate that 
Th1 cells seem to be more susceptible for Fas-mediated apoptosis 
than Th17 cells, both in MS patients and healthy controls (51).
Regulatory T cells are probably the most important contribu-
tors to the maintenance of peripheral tolerance. They are mainly 
defined by the expression of the transcription factor Foxp3 (52). 
Foxp3+ regulatory T cells are able to suppress proliferation of 
CD4+CD25− T cells (52, 53). It was found that interactions of 
thymocytes with MHC class II molecules expressed by mTECs 
were important for the induction of regulatory T cells (54). The 
possible role of different regulatory cell types in MS is discussed 
below in the respective sections.
immune Pathogenesis
The CNS as the target organ of the autoimmune response in MS is 
a special one. It is only a short time ago that it was recognized that 
the CNS is physiologically supervised by immune cells. Thereby, 
memory T cells are thought to play an important role (55).
It is believed that myelin-specific T cells have a crucial role in 
the pathogenesis of MS (56). Naïve myelin-specific T cells, which 
cannot access areas outside the secondary lymphoid tissues (57), 
are thought to be activated in the periphery, gain access to the 
CNS, and then be reactivated by CNS-resident cells presenting 
self-antigen (37). The CNS is extraordinarily shielded from the 
periphery by the existence of the brain–blood barrier (BBB) and 
the brain–cerebrospinal fluid (CSF) barrier. For activated T cells, 
there are three routes to enter the CNS, i.e., by crossing the BBB or 
the blood–CSF barrier or by migrating through the carotid arteries 
into the subarachnoid space (58). The most important pathogenic 
mechanisms in MS are outlined in Figure 1.
Peripheral Activation of T Cells
How T cells specific for CNS antigen are activated in the periphery 
remains unclear. However, their activation could result from a 
trigger by an infectious agent or from the presentation of myelin 
antigens in the cervical lymph nodes (37). Concerning the latter 
mechanism, CSF is drained via the nasal lymphatic system to the 
cervical lymph nodes. In experimental autoimmune encephalo-
myelitis (EAE) induced in marmosets, a relevant animal model of 
MS, myelin components were detected to be increased in APCs 
in cervical lymph nodes (59). A study using fine-needle biopsy 
material of cervical lymph nodes of MS patients and controls 
also detected more macrophages containing myelin basic protein 
(MBP) and PLP in MS patients than in controls (60). Therefore, 
APCs presenting myelin fragments in the cervical lymph nodes 
might contribute to an activation of naïve self-reactive T cells.
Role of infectious Agents
Apart from this concept, also infectious agents are considered to 
play an important role in triggering autoimmune diseases. In this 
context, a cross-talk between the innate and adaptive immune 
system might be relevant: infectious agents can activate APCs 
via Toll-like receptors (TLR). APCs can then contribute to the 
activation of self-reactive T cells (61).
Structural similarities between antigens of infectious agents 
and myelin proteins (molecular mimicry) can induce an activation 
of naïve autoreactive T cells which recognize peptides derived 
from infectious agents and self-antigens. Novel data indicate 
that cross-reactivities do not necessarily require nearly identical 
amino acid sequences. They also occur when some important 
motifs are conserved which make sure the overall structures of 
TCR–peptide–MHC interaction are similar (62). This suggests that 
cross-reactivities may happen frequently. There has been intensive 
research on possible infectious triggers of MS: it has been shown 
that T-cell clones specific for an immunodominant epitope of MBP, 
namely MBP85–99, also recognize viral peptides, e.g., of Epstein 
Barr virus (EBV), influenza A virus, herpes simplex virus, human 
papilloma virus (63), or human herpesvirus-6 (64). Concerning 
EBV, for example, MS patients seem to exhibit higher antibody 
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titers against certain antigenic components of the virus than 
controls even before the onset of MS (65). In EAE experiments, it 
could also be shown that a peptide from H. influenzae mimicking 
a PLP-peptide can actually induce CNS disease (66).
In the context of molecular mimicry, also self-mimicry has 
been observed. Transgenic myelin oligodendrocyte glycoprotein 
(MOG)-deficient mice expressing a MOG-specific TCR develop 
EAE due to a cross-reactivity between a MOG epitope and neu-
rofilament NF-M (67). Such cross-reactivities could play a role in 
the induction of axonal damage also in human MS.
Independently from cross-reactivities, infectious agents can 
lead to a disruption of tolerance to self-antigens by bystander 
activation. For example, demyelination can be induced when 
certain immunodeficient (RAG2−/− transgenic) mice are infected 
with mouse hepatitis virus (MHV), even though the CD8+ T cells 
they possess are neither specific for MHV nor for CNS antigen, 
when their T cells are activated by the antigen they recognize (68).
Recently, besides molecular mimicry and bystander activation, 
another interesting mechanism has been proposed: myelin-specific 
CD8+ T cells expressing a dual TCR specific for both MBP and viral 
antigens have been discovered. The activation of such T cells during 
viral infection might also induce autoimmune reactions (69).
Besides infectious agents, commensal microbiota could be 
of importance in the pathogenesis of the disease. EAE in mice 
expressing a transgenic TCR for MOG was found to depend on 
the presence of the commensal gut flora (70).
epitope Spreading
During the course of an autoimmune disease, otherwise physi-
ological immunological mechanisms like epitope spreading set 
in, which contribute to the perpetuation and diversification of 
the ongoing immune response. Epitope spreading means the 
expansion of the immune response to epitopes that are different 
from the initially targeted ones. This process is physiological 
and helpful in the fight against pathogens, but it also seems 
FiguRe 1 | Pathogenesis of MS. The exact pathogenesis of MS is not clear 
yet. However, it can be imagined that naïve autoreactive T cells exist because 
of imperfections in central and peripheral tolerance mechanisms. They might 
then become activated by antigen presentation in cervical lymph nodes or 
effects of molecular mimicry. Antigen presentation on disease-associated 
HLA-DR15-molecules might influence both the emergence and activation of 
autoreactive T cells. When autoreactive T cells reach the CNS by crossing the 
BBB, they encounter their target antigen and start an inflammatory cascade, in 
which other antigens become unveiled, triggering the process of epitope 
spreading.
to play an important role in the emergence of autoimmune 
responses.
In EAE, it could be shown that the immune response is first 
focused on a certain epitope and then spreads to other epitopes 
during the chronification of the disease (71, 72). Apart from intra-
molecular epitope spreading (e.g., within different MBP epitopes), 
also intermolecular epitope spreading, e.g., from MOG to MBP, has 
been observed in different EAE models (71, 73, 74). In different 
animal models of MS, it could also be shown that epitope spreading 
can begin in the CNS (75). Interestingly, also in an animal model 
using the CNS-resident virus Theiler’s murine encephalomyelitis 
virus for disease induction, T-cell reactivities against certain 
myelin epitopes emerged during the course of the disease, which 
were not due to molecular mimicry (76). Epitope spreading was 
reported to be associated with clinical relapses in animal models, 
as T cells reactive with epitopes the immune response had spread 
to could induce disease in other animals (74).
Both intramolecular (24, 25, 77–79) and intermolecular (80) 
epitope spreading has been observed in MS patients as well. 
However, it remains to be proven that this process also plays a 
pathogenic role in the disease, as some studies could not detect 
any associations with clinical exacerbations (77, 78).
Epitope spreading is also involved in other autoimmune 
diseases, complicating the search for the initial target antigens of 
the autoimmune response and complicating also the development 
of potent therapies which should ideally operate in all or many 
patients. Further understanding of this process will be crucial for 
designing efficient therapies.
immune Cells involved in the 
Pathogenesis of MS
Role of CD4+ T Cells
CD4+ T cells are widely considered major players in the patho-
genesis of MS.
FiguRe 2 | CD4+ T-cell differentiation. Naïve CD4+ T cells can differentiate 
into different T helper cell subsets. In MS, Th1 and Th17 cells are regarded to 
be disease-promoting, whereas regulatory T cells and Th2 cells seem to exert 
a protective effect. The exact role of Th9 and Th22 cells remains to be further 
clarified. Th1 cells, which predominantly produce TNF (95), IFN-γ, IL-2 (332), 
and lymphotoxin-α (333), are induced by IL-12 (95). Their master regulator is 
the transcription factor (TF) T-bet (334). They mainly interact with cytotoxic 
CD8+ T cells and macrophages (335). Th2 cells, which mainly interact with B 
cells (335), are induced by IL-4 and secrete IL-4, IL-5, IL-6, and IL-10 (101, 
333, 335). GATA-3 is the most important TF of Th2 cells (336). IL-6, TGF-β 
(93), and IL-23 (95) are important cytokines for the induction of Th17 cells 
producing IL-17, IL-6, TNFα (95), IL-21 (94), IL-22 (337). RORγt is the master 
regulator of this T-cell subset (338). Interestingly, TGF-β is also necessary for 
the induction of regulatory T cells, whereas IL-6 must be absent in this case 
(93, 117). The master regulator for the induction of regulatory T cells is the TF 
Foxp3 (52, 339). Regulatory T cells then produce TGF-β and IL-10 (117). 
Recently also Th9 cells and Th22 have been identified to be a discrete T-cell 
subset. The induction of Th9 cells is promoted by IL-4 and TGF-β (340). Th9 
cells produce IL-9 and to a lesser extent IL-10 (340, 341). Under the influence 
of TGF-β, Th2 cells can switch their phenotype and become Th9 cells (342). 
Master regulators for Th9 and Th22 cells have not been identified so far. 
Important factors for the induction of Th9 cells are PU.1, IRF, BATF, different 
STAT factors, and TGF-β-induced SMADS (341, 343). Priming of IL-22 
producing Th22 cells is promoted by IL-6 and TNF (103). The transcription 
factor aryl hydrocarbon regulator (AHR) seems to exert an important influence 
on IL-22 production (344).
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This is in part due to the fact that most of the genetic susceptibil-
ity for MS is associated with certain MHC class II alleles (81). CD4+ 
T cells have also been detected in MS lesions (82). Evidence also 
comes from a humanized mouse model: transgenic mice express-
ing the MS-associated DR2-molecule (DRA*0101/DRB1*1501), 
an MBP-specific TCR derived from MS patients and human CD4 
develop disease with symptoms very similar to those in MS and 
more severe symptoms than mice lacking CD4 expression (83). 
It is not clear yet, which CD4+ T helper cell subset (Th cell) exerts 
the most important influence on the disease. The subsets which 
are discussed most are Th1 cells and Th17 cells. Figure 2 gives an 
overview of different T-cell subsets, their signature cytokines, 
and important transcription factors.
Th1 Cells
Th1 cells have been and are seen as causative agents in MS, since 
MS-resembling animal models are driven by this T helper cell 
subset. There is also evidence that this T-cell subset might play a 
major role in human MS.
Administration of an altered peptide ligand (APL) based on 
an immunodominant epitope of MBP led to cross-recognition of 
MBP and the APL, resulting in exacerbations in some patients. 
The phenotype of the reactive T cells was skewed toward Th1 (84). 
Also other studies showed (partly by determination of chemokine 
receptor expression) that Th1 cells are especially increased in MS 
patients suffering a relapse compared to healthy controls or patients 
in remission (85–87). In PLP-specific T-cell lines isolated from 
MS patients during acute attacks, Th1 cytokines were found to be 
dominant (88) and also MBP-specific T-cell lines in MS patients 
produced significantly more IFN-γ than T-cell lines from controls 
(89). A correlation between IFN-γ-secretion (after stimulation with 
phytohemagglutinin) and contrast-enhancing lesions in MR was 
also detected (90). Higher levels of myelin-specific high-avidity 
CD4+ T cells were found in MS patients than in healthy controls, 
which exhibited a Th1 phenotype and higher IFN-γ production 
in MS patients (91). Recently, EAE experiments showed that Th1 
cells first infiltrate the CNS and are suppressed by regulatory T 
cells, which stops progression of the disease, whereas Th17 cells 
infiltrate the CNS later during the disease course (92).
Th17 Cells
In the last years, interleukin (IL)-17 producing Th17 cells have 
moved to the focus of research. Important factors for the induction, 
differentiation, and maintenance of the Th17 cell repertoire are 
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IL-6, transforming growth factor (TGF)-β (93), IL-21 (94), and 
IL-23 (95). IL-23-deficient mice have been shown to be unable to 
develop EAE (95). Interestingly, the development of regulatory 
T cells also requires TGF-β in the absence of IL-6 (93). IL-17 
transcripts have been shown increased especially in chronic silent 
MS lesions (82) and IL-17 positive cells were also found increased 
in MS lesions (96). In MS patients, more Th17 cells have been 
detected than in healthy controls and NMO patients (97). A study 
investigated T-cell subsets in patients with an aggressive disease 
course who received high-intensity chemotherapy followed by 
autologous stem cell transplantation, which induced remission 
in all patients. Interestingly, Th17 cell numbers were still decreased 
1 year after transplantation, whereas Th1 cells had reached normal 
levels, which might speak for an association between the decreased 
Th17 cells and the remission (98). Higher IL-17 production by 
myelin-reactive T cells has been reported in MS patients than in 
controls (99).
Th9 Cells and Th22 Cells
Recently, novel T-cell subsets have been detected whose role in 
MS has already begun to be investigated: Th9 cells reside mainly 
in the skin, where IL-9 might also play a role in the production of 
other cytokines like IFN-γ, IL-13, or IL-17 by T cells in the skin 
(100). Besides Th1 and Th17 cells, also Th9 cells could be shown 
to induce a milder form of EAE (101).
Similar to Th9 cells, Th22 cells were identified as a distinct T-cell 
subset to be present in the skin a few years ago (102, 103). Increased 
fractions of (myelin-reactive) Th22 cells have been reported in 
MS patients (104).
Regulatory T Cells
In MS patients, there does not seem to be a reduction of regulatory 
T cells in number (105–110), but there is some evidence that regu-
latory T cells might suppress autoreactive T cells less efficiently 
compared with healthy controls: regulatory T cells from MS 
patients seem to be less able to suppress effector T cells (106–108, 
110–112) and have a lower cloning frequency than regulatory 
T cells from healthy controls (106). However, it must be stated 
that some of these studies assumed the CD4+CD25hi phenotype 
as characteristic for regulatory T cells. However, after Foxp3 had 
been discovered, it became clear that by far not all regulatory 
T cells express CD25 at high levels (53). New regulatory T cells 
either mature in the thymus or stem from an expansion of regula-
tory T cells in the periphery. The latter mechanism physiologically 
gains importance with increasing age. In MS patients, there seems 
to be a selective lack of regulatory T cells released from the thymus, 
to which the observed functional impairment might be ascribed. 
The difference in thymic release of regulatory T cells between 
MS patients and healthy controls vanishes with increasing age of 
patients and controls (113–115). This might also partly explain 
why a functional impairment of regulatory T cells was detected in 
(younger) MS patients with relapsing-remitting disease (RR-MS) 
but not in (older) patients with secondary-progressive MS (SP-
MS) (109). Interestingly, Th17 cells can only be suppressed by a 
special subset of regulatory T cells expressing CD39, which were 
found reduced in number and less functional in RR-MS patients 
(but not in SP-MS patients) (116).
In EAE experiments, different observations concerning the 
function of regulatory cells during relapses were made: a study 
observed that regulatory T cells succeeded in suppressing naïve 
splenic autoreactive T cells, but not effector T cells from the CNS 
(in a cytokine milieu containing IL-6 and TNF) at the peak of 
disease (117). In another EAE study, however, regulatory T cells 
were found fully functional also during the peak of disease and 
were shown to alleviate disease by a putative suppression of Th1 
cells (92). Similarly, human T cells showed an enhanced expression 
of genes responsible for suppression of IFN-γ (118). These findings 
might indicate that during acute attacks the immune system starts 
a counterregulation, which might lead to remission. Interestingly, 
regulatory T cells were found increased in the CSF of MS patients 
compared to controls regardless of an active or inactive disease 
state (108). In a study investigating autoimmune responses after 
bone marrow transplantation in rats at the peak of EAE, an induc-
tion of regulatory T cells was shown, which are probable to make an 
important contribution to the achieved remission observed (119).
Role of CD8+ T Cells
Recently, also CD8+ T cells have drawn more attention. They are 
more frequently encountered in MS lesions than CD4+ T cells 
(120). CD8+ T-cell clones detected in brain lesions were shown 
to be still present in blood and CSF after several years (121). 
Another fact supporting the pathogenic role of CD8+ T cells is that 
MHC class II molecules interacting with CD4+ T cells are mainly 
expressed on professional APCs. However, MHC class I molecules 
are expressed on all nucleated cells, including oligodendrocytes 
or astrocytes and CD8+ T cells can interact with peptides bound 
to the MHC-I complex. In this context, CD8+ T cells were shown 
to be able to cause axonal damage (122). Increased reactivities of 
MBP-specific CD8+ T cells were shown to be present in MS patients 
compared with healthy controls. The CD8+ T cells identified by this 
study were predominantly memory T cells (CD45RO+) (123). An 
increased proportion of memory CD8+ T cells was also reported 
in the CSF of MS patients (124, 125). Elevated levels of granzyme, 
which is released by cytotoxic T cells, were found in the CSF of 
patients during relapse (126). So far, many attempts have failed 
to demonstrate stable disease-relevant CD8+ T-cell expansions to 
specific CNS-derived antigens in blood from MS patients. This is in 
contrast to some interesting studies in EAE, in which the relevance 
of myelin-specific CD8+ T cells has been shown. Importantly, CD8+ 
T cells specific for MBP can mediate a form of EAE in which a 
predominance of lesions is seen in the brain rather than in the 
spinal cord and less inflammation can be observed than in classical 
EAE (127).
On the other hand, also regulatory autoantigen-specific CD8+ 
T-cell populations exist, which are able to destroy pathogenic CD4+ 
T cells or mediate a suppression of their proliferation by interacting 
with DCs. Interestingly, these suppressive capabilities were found 
to be reduced during relapses (128–130).
Role of B Cells
Even though T cells are widely believed to play the central role in the 
pathogenesis of MS, there is also evidence supporting a pathogenic 
role of B cells. The importance of a possible role of B cells in MS is 
reflected in a study with rituximab, a B-cell depleting anti-CD20 
FiguRe 3 | The role of B cells in MS. B cells can play a role in autoimmune 
disease by different mechanisms which are depicted here: they can secrete 
potentially pathogenic antibodies, but also their function in cellular immune 
mechanisms are of importance, either by secreting proinflammatory cytokines 
and thereby influencing other immune cells or by acting as antigen-presenting 
cells. After B cells have encountered their specific antigen, they process it, 
present it on MHC and can become activated. As they are able to expand 
clonally, they are then capable to activate a big number of T cells.
June 2015 | Volume 6 | Article 3227
Riedhammer and Weissert Antigen presentation in multiple sclerosis
Frontiers in Immunology | www.frontiersin.org
monoclonal antibody (mAb), which was effective in reducing both 
lesion load measured by MRI and clinical relapses (131). The role 
of B cells in MS is schematically depicted in Figure 3.
Most MS patients show IgG oligoclonal bands in their CSF, 
indicating a local antibody production in the CNS (132). However, 
the targets of these locally produced antibodies have not yet been 
fully revealed. MOG-specific autoantibodies have been discovered 
in acute lesions of MS patients (133, 134).
Apart from their ability to secrete antibodies, the cytokines 
secreted by B cells can also influence T-cell proliferation in MS 
patients (135). A further important aspect in their role in cellular 
immunity is that they can serve as APCs (136). Their ability to 
expand clonally allows them to activate many T cells. In an EAE 
model depending on B and T cells, the functions of B cells as 
APCs were shown to be necessary for the induction of EAE instead 
of their ability to secrete antibodies (137). Memory B cells from 
RR-MS patients were shown to induce an increased response of 
CD4+ T cells to myelin antigens compared to memory B cells from 
healthy controls, also pointing toward a role of B cells as APCs 
(138). Clonally expanded B cells have been detected even in the 
CNS of recently diagnosed MS patients (139). Another interesting 
aspect concerning B cells as professional APCs is that the B-cell 
receptors (BCR) consisting of membrane-bound antibodies mostly 
recognize conformational epitopes of a protein, whereas T cells 
recognize linear peptides, processed before by APCs (140). The 
epitopes of an antigen presented by B cells might therefore be 
different from those presented by thymic epithelial and DCs, 
including the possibility that T cells specific for epitopes presented 
by B cells might escape central tolerance induction more easily.
Defects in peripheral (but not central) B-cell tolerance have 
been reported in MS patients, whereas, interestingly, defects in 
both peripheral and central B-cell tolerance have been detected 
in RA and T1D patients (141).
There are also B cells which can adopt regulatory functions, e.g., 
IL-10-secreting B cells, which can inhibit cytokine secretion (142). 
The induction of these IL-10-secreting B cells has been found to 
depend on the presence of IL-21 (which can be secreted, e.g., by 
Th17 cells) and CD40-dependent cognate interactions with T cells, 
whereas it can be inhibited by the presence of IFN-γ and TGF-β 
(143). It is not fully clear yet if the regulatory function of B cells 
might be defective in MS. Data on a possible reduction of IL-10-
secreting B cells in MS patients are contradictory, which is probably 
also due to different study designs (144–146). Interestingly, parasite 
infection with helminths in MS patients can induce these IL-10-
secreting regulatory B cells (147).
Role of Other Professional APCs
Apart from B cells, also other types of APCs have been shown to be 
of importance for antigen presentation in MS. Most work regarding 
the role of APCs in inflammation of the CNS has been conducted 
in rodent models. Unfortunately, the knowledge about APCs in 
human MS is still incomplete and not all gathered knowledge can 
be translated from rodents to humans. DCs are very important for 
linking innate and adaptive immune responses. Different types 
of DCs have been described in humans, namely the blood DCs 
plasmacytoid (p)DC (BDCA2), CD141+ DC (BDCA3), and CD1c+ 
(BDCA1), as well as the skin DCs, the Langerhans cells, and CD14+ 
DCs and inflammatory DCs in non-lymphoid tissue (148). All 
types are capable of presenting antigen, but differ in their expres-
sion pattern of molecules, migratory activity, cytokine secretion, 
and capacity for antigen presentation (149). For example, human 
CD141+ DC (BDCA3) express mainly TLR3, human CD1c + DC 
(BDCA1) mainly TLR2 and pDC (BDCA2) mainly TLR7 and 
TLR9 (150). This leads to different capabilities to react to certain 
pathogens in the environment. TLR stimulation itself results in DC 
maturation (151). DCs are required for the priming of naïve T cells 
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(152). Also the capability to cross-present antigen differs between 
different types of DCs (153). Even though DCs are obviously very 
important for the immunopathogenesis of MS, so far only limited 
data are available (154). Also macrophages have been shown to 
be capable to present antigen in MS (155). In rodent models, 
perivascular phagocytes in the CNS which present CNS antigens 
to T cells are of paramount importance in lesion development 
(156). Such cells can also be found in human MS (157). Within the 
CNS, microglia can serve as professional APCs (158). A change 
in the activation pattern of microglia is already seen very early in 
MS, which could potentially also speak for an increased capacity of 
antigen presentation (159, 160). Also astrocytes can express MHC 
class II molecules under certain conditions and present antigens in 
rodents (13, 161). In humans, so far the role of astrocytes in antigen 
presentation in CNS inflammation is still incompletely defined.
genetics of Multiple Sclerosis
Multiple sclerosis is not a classical hereditary disease. It is rather 
defined as a complex genetic disease. This is supported by twin 
studies, in which for monozygous twins the concordance rate is 
around 30%, and by findings in siblings of affected individuals 
who carry a risk of about 2% (162). Most probably, a combination 
of genetic and also environmental risk factors like smoking (163) 
contributes to its pathogenesis.
More than 100 risk loci have been identified so far in genome-
wide association studies (164), among which the variations 
within the HLA complex play the most important role. The 
most significant gene codes for the MHC class II, DR (81). The 
haplotype HLA-DR2 confers the largest part of the genetic risk 
for MS in Caucasians. In this MS-associated haplotype, two 
HLA-DRβ-chains (HLA-DRB1*1501 and HLA-DRB5*0101) 
pair with the α-chain HLA-DRA*0101, resulting in two heter-
odimers DR2a (HLA-DRA*0101, HLA-DRB5*0101) and DR2b 
(HLA-DRA*0101, HLA-DRB1*1501) expressed on the surface of 
APCs. In this haplotype, three alleles are in linkage disequilib-
rium and therefore mostly inherited together: HLA-DRB1*1501, 
HLA-DRB5*0101, and HLA-DQB1*0602 (165). Among these 
three alleles, HLA-DRB1*1501 confers the greatest genetic risk 
for MS. Other alleles with increased risk are HLA-DRB1*0301, 
HLA-DQB1*0201, HLA-DRB1*1303 (81). An association of the 
HLA-DR15 haplotype in MS with younger age at disease onset was 
reported, but no correlations with the clinical course, prognosis, 
or disease type could be detected (166). In contrast, some HLA-A 
alleles can be attributed some protective effect, most notably the 
allele HLA-A*0201, but also HLA-A*6801, HLA-A*0205, and 
HLA-A*0206 have recently been identified as protective (81). 
The expression of HLA-A*0201 in a humanized transgenic mouse 
model also protected animals from developing disease, possibly 
by influencing negative selection processes in the thymus (167).
Apart from the variations in the MHC-locus, 110 other risk-
conferring genes have been identified up to now in genome-wide 
association studies (164). Interestingly, a magnitude of them are 
genes related to the immune system, which corroborates the hypoth-
esis that MS is an autoimmune disease. Only some important genes 
can be discussed here. Genes regulating IL-2 signaling, which plays a 
pivotal role in T-cell activation, have been proposed to be associated 
with MS, e.g., the IFL-3 gene which regulates IL-2 expression by T 
cells, but also associations with the IL-2 receptor have been described 
(81, 164). Concerning the cytokine pathway, also genes coding for 
IL-7 and its receptor have been linked with a higher risk for MS. Less 
suppressive effects of regulatory T cells in MS patients was observed 
in the presence of cells expressing IL-7Rα (110), providing a possible 
link between the associated gene and a possible function in the 
disease. Also associations with genes coding for molecules involved 
in the costimulatory pathway like CD40 or CD80 have been detected. 
The possible role of defects in this mechanism has been discussed 
above. Several genes coding for signal transduction molecules (like 
STAT-3) have been described as well, which are highly relevant for 
immune cell function. There are also genes related to environmental 
risk factors such as vitamin D (e.g., CYP27B1) (81).
Table 1 shows some of the susceptibility loci of MS, RA, T1D, 
and MG in comparison. Even though this list is by far not exhaus-
tive, some interesting aspects can be comprehended: associations 
with MHC molecules are found not only in MS, but also in RA, 
T1D, MG, and other autoimmune diseases (168–171). There are 
also genes coding for molecules involved in similar costimulatory 
pathways like CD86 or CTLA-4, which contribute to the strength 
of the peptide–MHC interaction, or for cytokine pathways like 
IL2RA or TNF in the respective diseases (81, 168). This shows that 
there may be similar genetic traits leading to the development of 
different autoimmune diseases.
Genetic studies are able to reveal potential associations of cer-
tain genes with autoimmune diseases, but subsequent functional 
studies are necessary to determine the functional relevance of the 
identified genes. The functional relevance of most of the genes 
associated with different autoimmune diseases still remains to be 
clarified.
The relatively strong association of genes coding for MHC 
molecules with different autoimmune diseases suggests that the 
respective genetic variants might affect antigen presentation in a 
way that the emergence of an autoimmune disease is facilitated. 
Structural analyses of the MHC loci in different autoimmune 
diseases revealed certain characteristics of the binding groove, 
potentially leading to a preferential presentation of certain peptides 
(171). In general, MHC class II molecules are involved both in 
negative selection in the thymus by presentation of self-peptides 
and in antigen presentation in the target tissue. However, the exact 
mechanisms how risk is conferred by the MHC molecules still 
remain sketchy. An interesting new aspect was recently observed: in 
HLA-DR15+ individuals, increased autologous T-cell proliferation 
was found. In addition, the authors discovered that the HLA-DR15 
risk allele in MS is presented on itself, suggesting a possible role of 
this haplotype as an autoantigen and as a contributor to autologous 
proliferation (172). Interestingly, also in RA, DRB1*0401-β-chain-
peptides were found to be presented by themselves (173).
A future further understanding of the risk-conferring mecha-
nisms of the HLA genes will provide important new insights into 
the pathogenesis of the respective autoimmune diseases.
Discussed Autoantigens in MS
Principally, possible candidate autoantigens in MS include myelin 
antigens, neuronal antigens, and astrocyte-derived antigens. So 
TABLe 1 | Susceptibility genes in different autoimmune diseases.
Risk locus Function of associated gene/remarks Reference
Multiple sclerosis
HLA-DRB1*1501 Antigen presentation (81)
HLA-DRB1*0301
HLA-DQB1*0201
IL2RA = CD25 Mediation of IL-2 stimulation of T cells (81)
CD86 Role in costimulation, expressed on APCs (81)
TNFRSF1A Implication in TNF pathway (81)
TNFRSF14
TNFSF14
CYP27B1 Activation of vitamin D precursor (81)
Rheumatoid arthritis
HLA-DRB1*0401 Antigen presentation (170, 171, 
297–299)HLA-DRB1*0404
HLA-DRB1*0101
PTPN22 Down-regulation of T-cell activation (168, 300)
IL2RA = CD25 Mediation of IL-2 stimulation of T cells (168)
CTLA-4 Binds CD80 on APCs, inhibits T-cell 
activation
(168)
TNFAIP2 Implication in TNF pathway (168)
Type 1 diabetes
HLA-DQB1*0302 Antigen presentation (171, 301, 
302)HLA-DQ2
HLA-DRB1*0301
HLA-DRB1*0401
HLA-DRB1*0404
PTPN22 Down-regulation of T-cell activation (168, 303)
IL2RA = CD25 Mediation of IL-2 stimulation of T cells (168, 304)
CTLA-4 Binds CD80 on APCs, inhibits T-cell 
activation
(168, 305)
interferon-induced 
helicase 1 (IFIH1)
Pathogen recognition receptor for viral 
infection
(168, 306, 
307)
INS Codes for insulin (308)
Myasthenia gravis
HLA-B*08 Antigen presentation, association found in 
early-onset MG
(169)
PTPN22 Down-regulation of T-cell activation, 
association found in early-onset MG
(169)
TNIP1 (= TNFAIP3-
interacting protein)
Reduction of NFκB1 activation, 
association found in early-onset MG
(169)
Neuromyelitis optica
HLA-DPB1*0501 Antigen presentation, association in 
Asian, but not Caucasian NMO patients
(309, 310)
Autoimmune encephalitis
None reported so far
Some of the major disease susceptibility genes in MS, RA, T1D, MG, NMO, and AE 
reveal interesting similarities.
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far, most research has been done on myelin proteins, but there is 
evidence that also other antigens could serve as possible autoan-
tigens. In the following, some of the antigens derived from the 
myelin sheath are discussed in detail, which drew most attention 
of research in the past. Even though these are the most promising 
candidate autoantigens in MS, it will become clear that the data 
are not always consistent.
Myelin Basic Protein
Myelin basic protein is the second most abundant myelin protein 
after PLP. It is the only myelin component that can be found in 
both central and peripheral myelin. Thus, a peripheral activation of 
MBP-specific T cells seems more viable than of T cells reactive with 
other myelin components, from which they are normally separated.
It has been shown that there are MBP-reactive T cells in MS 
patients and healthy controls (19, 20). Several studies found 
significantly more IFN-γ-secreting T cells in response to differ-
ent MBP–peptides in MS patients than in controls, suggesting a 
quantitative increase of T cells exhibiting an activated phenotype 
(89, 174–176). Significantly more MBP-specific T-cell lines were 
found in the CSF of MS patients than of controls (23).
The central region of MBP84–102/MBP83–99, which can bind to 
several HLA-DRB molecules, was identified as immunodominant 
in several studies (177, 178). However, results varied with respect 
to differences in reactivities to MBP84–102 between MS patients and 
healthy controls. While some studies found increased reactivity to 
MBP84–102 in MS patients (20) or an enhanced response to MBP83–99 
in MS patients during relapse (87), others could not discover any 
discrepancies between the two cohorts (179–181). Krogsgaard 
et  al. showed by staining of CNS tissue of HLA-DR2-positive 
patients with a mAb specific for the HLA-DR2:MBP83–99 complex 
that this MBP epitope is locally presented in the CNS of MS 
patients, supporting a possible role as an autoantigen (182). Other 
epitopes described as immunodominant are MBP13–32 (177) and 
MBP144–163 (177)/MBP143–168 (23)/MBP151–170 (87). Interestingly, for 
high-affinity T cells, MBP83–99 was not immunodominant. Instead, 
MBP13–32, MBP111–129, and MBP146–170 were immunodominant in 
these T cells. Higher reactivities to these peptides were seen in 
MS patients (91).
After promising results in animal models, APLs based on 
the immunodominant epitope MBP83–99 were designed and 
administered in different phase II clinical trials. In one study, 
the APL successfully slightly reduced enhancing lesions at a 
certain dosage and skewed the T-cell response toward a Th2 
phenotype, so that the trial had to be stopped because of the 
occurrence of hypersensitivity reactions (183). However, in 
another study, the APL induced cross-recognition of MBP83–99 
and the APL by T cells in some patients, leading to exacerbation 
(84). One of the patients included in the latter study suffered 
two relapses under APL-treatment. Interestingly, before the first 
relapse, the number of T cells specific for MBP83–99 increased 
fivefold to decrease again after remission. In the second relapse, 
T cells specific for PLP190–209 were found expanded (80). This 
finding shows that myelin reactivity can correlate with disease 
progression and – besides other pieces of evidence – it also 
supports the notion of an immune pathogenesis of MS. In other 
studies, it could also be shown that T-cell reactivities against 
myelin components can correlate with disease progression, 
measured by using a disability score (174) or by assessment 
in MRI (176).
As MBP is an important candidate autoantigen in MS, its 
relationship with the disease-associated haplotype DR15 is of 
particular interest. Both HLA-DRB1*1501 and HLA-DRB5*0101 
contained in this haplotype can serve as restriction elements 
for MBP-reactive T cells (177). The immunodominant peptide 
MBP85–105, for example, seems to be able to be presented by 
both DRB1*1501 and DRB5*0101 (184, 185) and the complex 
DR2:MBP85–99 could be detected in tissue lesions (182).
TABLe 2 | Autoantigens in MS.
Autoantigen Remarks Reference
MBP T-cell responses and autoantibodies (91, 175, 311)
MOG T-cell responses and autoantibodies (193, 202)
PLP T-cell responses and autoantibodies (192, 311)
MAG T-cell responses and autoantibodies (312)
MOBP T-cell responses and autoantibodies (311, 313)
CNPase T-cell responses and autoantibodies (311, 314)
S100β T-cell responses (315)
Transaldolase T-cell responses and autoantibodies (316)
For overview of the autoantigens in MS discussed in this review, the respective antigens 
and the reactions they can evoke in MS patients are listed.
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A recent study showed that MBP is degraded by the 26S protea-
some without being ubiquitinated beforehand (186). Whether this 
discovery can be put in context with the pathogenesis of the disease 
remains to be resolved, but this shows very well how different 
aspects of antigen presentation might be involved in the emergence 
of autoimmune disease.
Proteolipid Protein
Proteolipid protein is the most abundant myelin protein. There are 
two isoforms: full-length PLP, which is nearly exclusively expressed 
in the CNS, and DM20, a splice variant of PLP missing a loop of 
25 amino acids, which is expressed in various peripheral organs 
like the thymus and lymph nodes (35). Only DM20 plays a role 
in negative selection in the thymus (27). The PLP loop contains 
the epitope PLP139–151, which seems predisposed to be a target of 
autoreactive T cells which can escape central tolerance induction 
in the thymus. However, enhanced reactivities to this epitope could 
only be detected in some studies (91), but not in others (181, 187).
T-cell responses to PLP seem to be heterogenous (188). 
Different epitopes have been identified as immunodominant in 
different studies (24, 180, 181, 187, 189, 190).
Some studies found higher proliferative responses (191) or 
higher precursor frequencies (23) of PLP-specific T-cell lines 
in MS patients. Higher reactivities to some PLP epitopes were 
detected in some studies in MS patients compared to controls (180, 
189). However, other studies could not detect any differences in 
reactivities against their epitopes detected as immunodominant 
between patients and controls (188, 190).
Myelin Oligodendrocyte glycoprotein
Myelin oligodendrocyte glycoprotein is a minor component of the 
myelin sheath. It could not be detected in the human thymus and 
might therefore evade presentation in central tolerance induction, 
supporting its possible role as an autoantigen (35). Many different 
studies have so far assessed T- and B-cell responses to this antigen.
Some studies have detected higher numbers of IFN-γ-
secreting cells (192, 193), higher numbers of T cells reactive 
with DRB1*0401/MOG97–109-tetramer (194), higher proliferative 
responses of peripheral blood lymphocytes (PBL) (195), or higher 
proliferative responses of T cells to certain MOG epitopes (196) 
in MS patients than in healthy controls.
Interestingly, there are also data that MOG could play a role 
in humoral autoimmunity in MS. MOG-specific autoantibodies 
have been discovered in acute lesions of MS patients (133, 134). 
Some studies also found higher levels of MOG-specific anti-
bodies or higher antibody responses to certain MOG epitopes 
in the serum of MS patients than in control sera (197–202) or 
in certain clinical subgroups of MS patients (203). However, 
other studies did not observe any differences between the sera 
of MS patients and healthy controls or patients with other 
neurological diseases, or did not detect any MOG-antibodies 
at all (134, 204, 205). The antibodies were shown to be actually 
demyelinating in an EAE experiment (200).
Data about a possible association of anti-MOG-antibodies (and 
anti-MBP-antibodies) with a progression from CIS to definite MS 
remain controversial (202, 206–210), rendering the use of these 
antibodies as biomarkers difficult.
There are interindividual differences concerning the specific 
MOG epitopes causing an antibody response (198, 211) and T-cell 
reactivities (212), which might also depend on the individual HLA 
type (213).
Important new data also indicate that MOG can interact 
with DC-specific intercellular adhesion molecule 3-grabbing 
non-integrin (DC-SIGN), which can induce IL-10 secretion 
and suppress T-cell proliferation. This interaction depends on 
the correct glycosylation state of MOG, which can be altered 
during inflammation (214). These findings could indicate that 
altered glycosylation of MOG can potentially result in disruption 
of tolerance and induction of anti-MOG-specific T- and B-cell 
responses.
Other and Novel Autoantigens in MS
Besides the above described antigens MBP, MOG, and PLP, 
myelin-associated antigen (MAG), myelin-associated oligo-
dendrocyte basic protein (MOBP), and 2′,3′-cyclic-nucleotide 
3′-phosphodiesterase (CNPase) have been shown to evoke T- or/
and B-cell responses in patients with MS. Apart from these myelin 
components, other antigens like S100β protein or transaldolase 
H are discussed as autoantigens in MS (56). While a-B-crystallin 
was first thought to be an autoantigen in MS (215), more recent 
data indicate that it serves as a chaperone and does not fulfill the 
criteria of an autoantigen (216). In another study, 300 peptides 
presented on MHC class I and MHC class II molecules in the 
CNS of MS patients were eluted and identified. Among them, 
widely investigated proteins like MBP were found, but also non-
myelin proteins could be detected (217). Table  2 summarizes 
the autoantigens discussed in MS. For a comparison with other 
autoimmune diseases, Tables 3 and 4 summarize some important 
candidate autoantigens in MG, NMO, T1D, RA, and AE.
Autoantigens in Other Autoimmune 
Diseases
Myasthenia gravis
Myasthenia gravis is a neurological disease characterized by muscle 
weakness which worsens by exertion and improves by rest (218).
Some decades ago, antibodies directed against nicotine 
acetylcholine receptors (nAChR) were detected in most MG 
patients (219, 220), which could also be shown to be pathogenic 
by a transfer of sera to mice (221). A considerable part of the 
TABLe 3 | Autoantigens in other (peripheral) autoimmune diseases.
Autoantigen Remarks Reference
Myasthenia gravis
nAChR Antibodies in most MG patients (223)
MuSK Antibodies in “seronegative” MG patients (222)
LRP4 Antibodies in “seronegative” MG patients (224, 317)
Diabetes mellitus type 1
Insulin Antibodies already in prediabetics (253, 254)
T-cell reactivities to different epitopes
IA-2 Antibodies in 50% of diabetics (257, 259)
T-cell responses in context of HLA-DR4
GAD-65 Antibodies in >80% of diabetics (256, 
260–262)Elevated T-cell responses
ZnT8 Antibodies in 60–80% of diabetics at onset 
of disease
(258, 263)
Elevated T-cell responses
IGRP Elevated T-cell responses (264)
Chromogranin A Elevated T-cell responses (265)
Rheumatoid arthritis
Fc-part of 
immunoglobulins
Antibodies in >80% of RA patients 
(rheumatoid factor)
(277)
Citrullinated antigens Antibodies before and during disease 
course
(281, 282)
Specific B cells in synovial fluid
Carbamylated 
antigens
Antibodies in 45% of RA patients (286)
Collagen Antibodies to post-translationally modified 
forms
(287, 288)
Antibodies to denatured forms
65-kDa heat-shock 
protein
Antibodies in RA patients (279)
Cartilage 
glycoprotein-39
T-cell responses in RA patients (275)
Aggrecan G1 T-cell responses in RA patients (276)
Important (candidate) autoantigens of MG, T1D, and RA are shown. It can be 
comprehended that in T1D and RA, there are several candidate autoantigens evoking 
B- and/or T-cell responses, whereas in MG, the target antigens are already more clear.
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10–20% of MG patients who had long been assessed as seron-
egative for nAChR-autoantibodies could be shown to possess 
autoantibodies against the receptor tyrosine kinase MuSK (222) 
or still possess low-affinity antibodies against the nAChR by 
employing a more sensitive assay (223). More recently, also 
low-density lipoprotein receptor-related protein (Lrp4) was 
identified to be a target of autoantibodies in a small proportion 
of seronegative MG patients (224). These findings point toward 
B cells playing the central role in the pathogenesis of MG. But 
also nAChR-specific T lymphocytes have been discovered (22, 
225), consistent with necessary T cell help and activation for an 
autoantibody production by B cells. Regulatory T cells isolated 
from thymi of MG patients showed a reduced suppressive 
capability (226).
Even though B cells and their antibodies seem to play a crucial 
role for the disease, its exact pathogenesis could not be revealed 
yet. Complement activation by autoantibodies and crosslinking 
nAChR leading to their degradation were suggested to be under-
lying pathogenic mechanisms of the nAChR-autoantibodies 
(218). But still, the emergence of an autoimmune disease always 
requires an interplay of different immune cell types and T cells 
are probable to play an important role. Like in MS, as discussed 
TABLe 4 | Autoantigens in NMO and autoimmune encephalitides as 
examples of other CNS autoimmune diseases.
Autoantigen Remarks Reference
Neuromyelitis optica
AQP-4 Antibodies in 73% of NMO patients (229)
MOG Antibodies in 7% of NMO-spectrum disorder 
patients
(238)
Autoimmune encephalitides to membrane antigens
NMDA-receptor Antibodies in patients with limbic 
encephalitis, psychotic behavior
(289, 291)
AMPA-receptor Antibodies in patients with limbic 
encephalitis
(289)
GABAA-receptor Antibodies in patients with anti-GABA-A 
receptor encephalitis
(318)
GABAB-receptor Antibodies in patients with limbic 
encephalitis
(289)
Gly-receptor Antibodies in patients with limbic 
encephalitis, Stiff person syndrome
(289)
DPPX Antibodies in patients with anti-DPPX-
associated encephalitis
(319)
GluR5 Antibodies in patients with anti-GluR5 
encephalitis
(320)
VGKC-complex Antibodies in patients with limbic 
encephalitis, faciobrachial dystonic seizures, 
Morvan’s syndrome, neuromyotonia
(289)
Autoimmune encephalitides to intracellular antigens
Hu T cells and antibodies in patients with  
anti-Hu encephalitis
(321, 322)
Jo (323, 324), Ri (325), Ma1 (326), Ma2 (327), Zic4 (328), GAD-65 (329), 
CRMP5 (330), and amphiphysin (331) as target of autoantibodies in patients 
with the respective encephalitis forms
above, it could also be shown that B cells can serve as APCs in 
MG (227).
Compared to MS, the autoimmune origin of the disease is 
evidenced very clearly and the nAChR is well characterized as 
the target structure of the autoimmune response. But still, the 
exact etiology of the disease remains to be clarified.
Neuromyelitis Optica
Neuromyelitis optica is a demyelinating disease of the CNS 
characterized by optic neuritis and longitudinally extensive 
transverse myelitis (228). Originally, the disease was not differ-
entiated from MS, but important differences between NMO and 
MS will be pointed out in the following. Autoantibodies directed 
against aquaporin-4 (AQP-4)-channels were discovered in 73% 
of sera of NMO patients but not in sera of MS patients (229, 
230). Anti-AQP-4 antibodies also seem to have some predictive 
value concerning the clinical course of the disease (231). AQP-
4-channels are expressed on astrocytic foot processes at the BBB 
(230, 232). Pathological findings indicate a complete loss of AQP-4 
in NMO lesions, whereas in MS, AQP-4 staining was enhanced in 
the periplaque white matter of active lesions, and absent in inactive 
lesions (232). There is evidence that these antibodies might also be 
pathogenic. They were found to have cytotoxic effects on astrocytes 
in the presence of complement (233, 234), increase natural killer 
cell-mediated cytotoxicity (235, 236), complement-mediated 
involvement of granulocytes (235, 236), and the permeability of 
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the BBB (235). In animal studies, a more severe disease course of 
EAE displaying features of NMO was observed (236, 237).
There are also NMO patients who are seronegative for AQP-
4-antibodies. In 7% of patients with NMO-spectrum disorders 
(NMOSD), i.e., patients presenting either with isolated transverse 
myelitis or optic neuritis, MOG-antibodies were discovered (238). 
Also AQP-4-antibody-negative patients with classical signs of 
NMO have been described to possess antibodies to MOG (239). 
However, MOG-antibodies seem to be less specific for NMO. 
MOG-antibody-positive patients with NMOSD also seem to show 
a milder clinical course than AQP-4-positive patients (238). Data 
in animal models of NMO indicate that the T-cell response is not 
mandatory for the development of NMO if AQP-4 antibodies are 
present in serum or CSF. The access of the antibodies to the CNS 
and their binding to astrocytes appears to be most important (240, 
241). Consistent with an important role of a loss of B-cell tolerance, 
regulatory B cells were found decreased in NMO and secreted less 
IL-10 (97). Nevertheless, T cells seem to be mandatory for the 
initial emergence of plasma cells which secrete AQP-4-specific 
antibodies (242, 243).
So even though NMO can sometimes clinically resemble MS, 
the mechanisms of their pathogeneses seem to differ greatly in 
regard to the autoimmune target and the emerging immune 
response.
Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which the β-cells in 
the Langerhans islands of the pancreas are destroyed, resulting 
in a lack of insulin. It is thought that T cells play a more decisive 
role in β-cell destruction than B cells, but B cells were shown to 
be relevant by producing autoantibodies against islet cell antigens 
already in prediabetic phases and by presenting antigen to CD4+ 
and CD8+ T cells (244). Concerning CD4+ T cells, Th1 and Th17 
cells seem to be the most significant T helper cell subsets for T1D. 
The animal model of T1D is mainly driven by Th1 cells, but there 
is also evidence of a role of Th1 cells in human T1D (245). More 
IL-17-secreting T cells were detected in recent-onset T1D and 
IL-17 seems to promote the inflammatory response to β-cells 
(246, 247). Th17 cells were also found increased in pancreatic-
draining lymph nodes (248). Insulin-specific CD8+ T cells could 
be associated with an autoimmune destruction of transplanted 
Langerhans islands (249). CD8+ T cells were also more frequent in 
pancreatic-draining lymph nodes than in those of controls (248). 
Similar to MS, defects in the suppressive capabilities of regulatory 
T cells have been detected (250). This was also shown for T cells 
residing in pancreatic-draining lymph nodes (248). On the other 
hand, also a higher resistance of effector T cells to suppression 
by regulatory T cells has been reported (251). Possible defects in 
central and peripheral B-cell tolerance were also reported (141). 
Epitope spreading also seems to be an important mechanism in the 
autoimmune response in T1D, intermolecular epitope spreading 
was observed even before the clinical onset of the disease (252).
Different antigens are discussed as autoantigens in T1D. Among 
them, insulin seems to play a major role: in some diabetics, anti-
bodies to insulin can be discovered before insulin treatment (253). 
Most T1D patients were shown to possess CD8+ T cells reactive 
with proinsulin peptides (254).
Islet cell autoantibodies (ICA) were detected to be more fre-
quent in T1D patients and were also suggested to have predictive 
value (255). Many T1D patients also exhibit antibodies against 
the enzyme glutamic acid decarboxylase (GAD)-65, which is 
expressed in neurons and in pancreatic β-cells (256). Subsequently, 
also autoantibodies against tyrosine phosphatase-like islet-antigen 
2 (IA-2) (257) and against the zinc transporter ZnT8 (258) were 
detected in diabetics.
In addition to insulin, T-cell reactivities against several other 
antigens were identified: not only autoantibodies, but also T-cell 
responses against IA-2 and GAD-65 were detected, especially in the 
context of HLA-DR4 (259–262). Also ZnT8 seems to evoke elevated 
T-cell responses in diabetics (263). Human PBMCs of patients with 
recent-onset diabetes also showed elevated IFN-γ secretion when 
stimulated with islet-specific glucose-6-phosphatase catalytic 
subunit-related protein (IGRP), supporting a possible role as an 
autoantigen (264). Chromogranin A was also discovered to be a 
relevant T-cell antigen in human T1D (265).
On the whole, there are several features MS and T1D have 
in common. Their animal models seem to be mainly driven by 
autoreactive Th1 cells, but both animal and human data indicate 
also an important role of Th17 cells and an impaired function 
of regulatory populations. Their major genetic risk loci code for 
MHC molecules and several T- and B-cell antigens have been 
suggested as putative target structures. Interestingly, T1D has also 
been reported to display cyclic processes in the ongoing β-cell 
destruction, characterized by damage by autoreactive T cells, 
epitope spreading, β-cell proliferation, and suppressive activities by 
regulatory T cells (266). This could resemble a relapsing-remitting 
course as found in most MS patients.
Rheumatoid Arthritis
In RA, it is not fully resolved whether T cells or B cells play the 
more important role in its pathogenesis, for there are important 
aspects supporting a relevance of both cell types. T- and B-cell 
clones have been detected in the joints of RA patients, partly 
even the same clones were found in different affected joints 
(267, 268). Like in MS and T1D, a pathogenic role of Th1 and 
Th17 cells has been suggested. Th1 cells were encountered much 
more frequently than Th17 cells in the joint of RA patients with 
established disease (269). On the other hand, increased numbers 
of Th17 cells and higher IL-17 levels were found in peripheral 
blood and synovial fluid of patients with untreated early RA 
(270). Part of their pathogenicity might be due to the effect 
of IL-17, which among other cytokines leads to an increased 
production of TNF-α (271), which plays a pivotal role in the 
pathogenesis of RA. Th17 memory cells can also induce secre-
tion of proinflammatory cytokines by synovial fibroblasts (272). 
Regulatory T cells in RA have been found less able to suppress 
the production of proinflammatory cytokines like TNFα in 
acute phases of the disease (273). B cells do not only secrete 
potentially pathogenic antibodies, but also their function in 
cellular immunity plays a role in RA, as T cells were shown to be 
activated by B cells in synovitis (267). Defects in both peripheral 
and central B-cell tolerance were observed (141). The efficacy 
of a treatment with rituximab confirms a pathogenic role of B 
cells in the disease (274).
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Like in MS and T1D, several different antigens are discussed 
as autoantigens in RA; some of the possible targets in RA will be 
discussed here.
Examples for putative T-cell targets in RA include the human 
cartilage glycoprotein-39 (275) and aggrecan G1 (276). Some 
autoantibodies target the Fc-part of immunoglobulins (277). 
These antibodies are also referred to as the “rheumatoid factor.” The 
presence of the rheumatoid factor is associated with a more severe 
disease course (278). Elevated autoantibodies against 65-kDa heat-
shock protein have also been detected in RA patients compared to 
controls (279). An interesting aspect of the autoimmune response 
in RA is that it also seems to be directed against post-translational 
modifications of antigens like citrullination or carbamylation 
(280). Antibodies against different citrullinated antigens are found 
significantly more often in RA patients compared to controls and 
are elevated already before the onset of disease (281). A considerable 
proportion of B cells found in synovial fluid have been observed 
to secrete antibodies directed against citrullinated antigens (282). 
Epitope spreading of the antibody response to different citrullinated 
peptides has been observed even before the clinical onset of RA 
(283). Data from animal models indicate that antibodies directed 
against citrullinated antigens are pathogenic and worsen arthritis 
(284). Human data indicate that anti-cyclic citrullinated antibod-
ies can lead to complement activation (285). Independently from 
APCA, antibodies directed against carbamylated antigens have been 
discovered in about 45% of RA patients (286). In early stages of RA, 
autoantibodies against post-translationally modified collagen have 
recently been detected in over 90% or RA patients (287). During 
the course of the disease, also higher antibody titers to denaturated 
collagen were found in RA patients than in controls (288).
Like T1D and MS, also RA shows an HLA-association, an 
important role of Th1 and Th17 cells and possible defects in 
regulatory mechanisms. In contrast to MS and T1D, autoimmune 
responses to post-translational modifications have been studied 
more extensively in RA.
Autoimmune encephalitides
In the last years, several antibody-mediated AE were discovered 
with immune responses to membrane-bound proteins, which 
respond well to immunotherapies like plasmapheresis. Symptoms 
range from psychiatric symptoms, such as personality and behavio-
ral change, agitation and paranoia, to epilepsy, amnesia, and many 
others. Antibodies against different neuronal antigens were found 
in different disorders, with most autoantigens directed against cer-
tain ion channel proteins or receptors involved in brain signaling. 
For example, antibodies against N-methyl-D-aspartate (NMDA) 
receptors, alpha-amino-3-hydroxy-5-methyl-4-isoxazoleprionic 
acid (AMPA)-receptors, gamma-aminobutyric acid (GABA) type 
A or B receptors, glycine receptors (GlyR), dipeptidyl-peptidase-
like-protein 6 (DPPX), metabotrophic glutamate receptor 5 
(GluR5), or voltage-gated potassium channels were detected in 
patients with different forms of autoimmune encephalitis (289).
As an example, only anti-NMDA-receptor encephalitis is briefly 
discussed here, as there is evidence of a direct pathogenic relevance 
of the autoantibodies by leading to receptor internalization (290). 
The occurring autoantibodies were detected to be directed against 
heteromers of the NMDA-receptor containing the subunits NR2B 
or NR2A (291). A pathological study barely found markers of 
cell cytotoxicity, but large deposits of IgG, pointing toward a 
functionally primary causative role of antibodies produced by B 
cells instead of cellular immunity (292). Anti-NMDA-receptor 
encephalitis as well as other types of autoimmune encephalitis can 
be of paraneoplastic origin. Associations of anti-NMDA-receptor 
encephalitis with ovarian teratoma have been described (291). The 
role of T cells in these encephalitis forms is not well established 
yet. Possibly they are instrumental for disease initiation by helping 
B cells to secrete pathogenic antibodies.
There are many intracellularly located target antigens that can 
cause autoimmune encephalitis. Many of these are induced by 
paraneoplastic mechanisms, but there are also pure autoimmune 
conditions. Most probably, T cells and especially CD8+ T cells 
are of paramount importance by leading to tissue damage (293, 
294). For diagnoses, antibodies against such antigens are pivotal. 
Antigens that have been described as target antigens and to which 
also antibodies are found in patients are Hu, Yo, Ri, Ma1, Ma2, 
Zic4, GAD-65, CRMP5, and amphiphysin (Table 4).
ways to the Autoantigens
Principally, possible autoantigens can be determined by testing the 
immune reaction against antigens that can be assumed to be tar-
geted in an autoimmune disease because of certain characteristics 
of the disease (e.g., myelin antigens in the demyelinating disease 
MS). As described above, there has already been much research 
investigating the role of myelin antigens in MS.
Another way to determine possible autoantigens would be 
first to identify possible candidate autoantigens of the disease, 
e.g., by elution of peptides presented on MHC molecules of 
APCs in affected individuals or by screening sera of patients for 
autoantibodies, and afterwards test the actual functional role of 
the findings. The approach to elute peptides presented on APCs in 
autoimmunity has been successfully applied in research on differ-
ent autoimmune diseases like RA or T1D (173, 259, 260, 295), but 
also in MS (217). The eluted peptides from the CNS of MS patients 
might have a high potential as autoantigens, since antigen presenta-
tion in the healthy CNS is low. In active MS lesions, however, MHC 
molecules have been observed to be upregulated (82).
Conclusion
In all autoimmune diseases, the importance of the role of pep-
tide–MHC–TCR interactions cannot be underestimated. Antigen 
presentation is in the center of every autoimmune disease, influ-
encing both tolerance induction in the thymus and self-antigen 
recognition and immune cell activation in the periphery. This 
is underlined by the fact that the genetic risk factors of many 
autoimmune diseases are conferred by genes involved in antigen 
presentation. The onset of several physiological immune mecha-
nisms like epitope spreading obscures the search for the primary 
underlying target of the ongoing immune attack. This underlines 
the great importance of studying immune reactions in recently 
diagnosed patients or even before diagnosis for eventually being 
able to determine the primary event in MS and other diseases of a 
putative autoimmune origin. On the other hand, for more efficient 
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therapy development, the processes which set in later during the 
course of an autoimmune disease must be taken into account as 
well. In the discussed autoimmune diseases, the emergence of 
neo-antigens by tissue destruction and epitope spreading play a 
role. To give only one example, this might be a reason for the 
failure of therapeutic trials with peptides based only on MBP in 
MS treatment. Recently, evidence was adduced that the native con-
formation of an antigen is of importance for inducing an immune 
response (296). This is of great relevance for studies investigating 
possible autoantigens, since antigens are not always employed in 
their native conformation; which further complicates the search 
for the principal autoantigen(s).
It is striking that many susceptibility genes conferring risk 
for different autoimmune diseases code for HLA genes, further 
emphasizing the extreme relevance of antigen presentation for 
autoimmune diseases. A comparison of MS with other autoim-
mune diseases is interesting also in other respects: the exact 
pathogenesis has not been identified yet in either autoimmune 
disease. The determination of the (primary) autoantigens is a 
crucial step in understanding the pathogenesis of a disease. 
But even when target antigens have been identified like in MG 
or NMO, the pathogenic mechanism can still remain unclear. 
Neither has it been resolved which cell types play the dominant 
role in the induction of an autoimmune disease. The concept 
of MS being a “T-cell-mediated” autoimmune disease and MG 
being a “B-cell-mediated” autoimmune disease must be reevalu-
ated. Data indicate that autoimmune diseases emerge from a 
complex interplay of many different factors of the immune 
system.
Comparisons of MS with RA or T1D show that there are more 
diseases whose target antigen(s) have not been fully identified. 
Until an unequivocal target of the immune attack has been identi-
fied in MS and other diseases, there will also remain the question 
if the causative factors might even be heterogenic.
At all events, a detailed understanding of the etiology of the 
discussed autoimmune diseases is an enormous challenge, but will 
remain a prerequisite for the development of new, specific, and 
more efficient treatment options.
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